Abstract: Diterpenoid alkaloids are isolated from plants of the genera Aconitum, Delphinium, and Garrya (Ranunculaceae) and classified according to their chemical structures as C 18 -, C 19 -or C 20 -diterpenoid alkaloids. The extreme toxicity of certain compounds, e.g., aconitine, has prompted a thorough investigation of how structural features affect their bioactivities. Therefore, natural diterpenoid alkaloids and semi-synthetic alkaloid derivatives were evaluated for cytotoxic effects against human tumor cells [A549 (lung carcinoma), DU145 (prostate carcinoma), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen receptor-positive, HER2-negative breast cancer), KB (identical to cervical carcinoma HeLa derived AV-3 cell line), and multidrug-resistant (MDR) subline KB-VIN]. Among the tested alkaloids, C 19 -diterpenoid (e.g., lipojesaconitine, delcosine and delpheline derivatives) and C 20 -diterpenoid (e.g., kobusine and pseudokobusine derivatives) alkaloids exhibited significant cytotoxic activity and, thus, provide promising new leads for further development as antitumor agents. Notably, several diterpenoid alkaloids were more potent against MDR subline KB-VIN cells than the parental drug-sensitive KB cells.
Introduction
Cancer therapy mainly involves surgery, chemotherapy, radiation therapy, immunotherapy, monoclonal antibody therapy, and hormone therapy. Chemotherapy generally refers to the use of cytotoxic drugs to treat cancer. Plant alkaloids are one major class of chemotherapeutic drugs [1] [2] [3] [4] [5] [6] [7] [8] [9] . Chemotherapeutic drugs that affect cell division by preventing the normal functioning of micro-tubules include the vinca alkaloids.
Numerous diterpenoid alkaloids have been isolated from various Aconitum, Delphinium, and Garrya (Family Ranunculaceae) species and are classified according to their chemical structures as C 18 -, C 19 or C 20 -diterpenoid alkaloids ( Figure 1 ) [10, 11] . The C 19 -diterpenoid alkaloids may be divided into six types: aconitine, lycoctonine, pyro (C 8 =C 15 or C 15 =O), lactone (δ-valerolactone rather than cyclopentyl C-ring), 7,17-seco, and rearranged ones [10, 11] . Most of the isolated C 19 -diterpenoid alkaloids are aconitine-and lycoctonine-types and include aconitine, mesaconitine, hypaconitine and jesaconitine, all of which are extremely toxic. The C 20 -diterpenoid alkaloids may be divided into ten types: atisine, denudatine, hetidine, hetisine, vakognavine, napelline, kusnezoline, racemulosine, arcutine, and tricalysiamide [10, 11] . Most of the isolated C 20 -diterpenoid alkaloids are atisine-, hetisine-, and napelline-types and include atisine, kobusine, pseudokobusine and lucidusculine, which are far less toxic [12] . The pharmacological properties of the C19-diterpenoid alkaloids have been studied extensively and reviewed [12] . Aconitine is a toxin that exhibits activity both centrally and peripherally, acting predominantly on the cardiovascular and respiratory systems by preventing the normal closing of sodium channels [12] . This extreme toxicity resulted in the use of Aconitum extracts as poisons in hunting and warfare [13] , although extracts were also used as traditional medicines by oral and topical routes. For example, the roots of Aconitum plants have been used as "bushi", an herbal drug in some prescriptions of traditional Japanese medicine for the treatment of hypometabolism, dysuria, cardiac weakness, chills, neuralgia, gout, and certain rheumatic diseases [14] . However, proper processing is essential to reduce the content of toxic alkaloids and avoid inadvertent poisoning [15] [16] [17] . Such obstacles encourage a good understanding of the relationships between structure and cytotoxic activity of aconitine and related compounds before they can be considered for modification and development as chemotherapeutic agents.
Our previous study demonstrated the effects of various naturally occurring and semi-synthetic C19-and C20-diterpenoid alkaloids on the growth of the A172 human malignant glioma cell line [18] . Antitumor properties and radiation-sensitizing effects of various types of novel derivatives prepared from C19-and C20-diterpenoid alkaloids were also investigated [19] . Two novel hetisine-type C20-diterpenoid derivatives showed significant suppressive effects against the Raji non-Hodgkin's lymphoma cell line [20] . In addition, the effects of various semi-synthetic novel hetisine-type C20-diterpenoid alkaloids on the growth of the A549 human lung cancer cell line were examined and subsequent structure-activity relationships for the antiproliferative effects against A549 cells were considered [21] . Since 2012, several diterpenoid alkaloid components and their derivatives exhibited antiproliferative activity against human tumor cell lines, including A549 (lung carcinoma), DU145 (prostate carcinoma), MDA-MB-231 (estrogen and progesterone receptor-negative & HER2-negative triple-negative breast cancer), MCF-7 (estrogen receptor-positive, HER2-negative breast cancer), KB (identical to cervical carcinoma HeLa derived AV-3 cell line), and multidrug-resistant (MDR) subline KB-VIN [P-glycoprotein (P-gp) overexpressing vincristine-resistant KB subline]. Among such alkaloids, C19-diterpenoid (e.g., lipojesaconitine, delpheline, and delcosine derivative) and C20-diterpenoid (e.g., kobusine and pseudokobusine derivatives) alkaloids have shown significant antiproliferative activity, as well as provided promising new leads for further development as antitumor agents.
Antiproliferative Activity of C19-Diterpenoid Alkaloid Derivatives

Aconitine-Type C19-Diterpenoid Alkaloids
The tested aconitine-type C19-diterpenoid alkaloids included 21 natural alkaloids, aconitine (1), deoxyaconitine (2) , jesaconitine (3), deoxyjesaconitine (4), aljesaconitine A (5), secojesaconitine (6) , mesaconitine (8) , hypaconitine (9) , hokbusine A (10), 14-anisoyllasianine (12) , N-deethylaljesaconitine A (13), aconine (14) , lipomesaconitine (15) , lipoaconitine (16) , lipojesaconitine (17) , neolinine (18) , neoline (19) , 14-benzoylneoline (20) , isotalatizidine (21) , karacoline (22) , and 3-hydroxykaracoline (23) , isolated from the rhizoma of Aconitum japonicum THUNB. subsp. subcuneatum (NAKAI) KADOTA [22] [23] [24] [25] [26] [27] [28] (Figure 2 ). Two synthetic aconitine-type C19-diterpenoid alkaloids, 3,15-diacetyljesaconitine (7) Figure 1 . Classifications, general structures and numbering systems for C 18 -, C 19 -, and C 20 -diterpenoid alkaloids.
The pharmacological properties of the C 19 -diterpenoid alkaloids have been studied extensively and reviewed [12] . Aconitine is a toxin that exhibits activity both centrally and peripherally, acting predominantly on the cardiovascular and respiratory systems by preventing the normal closing of sodium channels [12] . This extreme toxicity resulted in the use of Aconitum extracts as poisons in hunting and warfare [13] , although extracts were also used as traditional medicines by oral and topical routes. For example, the roots of Aconitum plants have been used as "bushi", an herbal drug in some prescriptions of traditional Japanese medicine for the treatment of hypometabolism, dysuria, cardiac weakness, chills, neuralgia, gout, and certain rheumatic diseases [14] . However, proper processing is essential to reduce the content of toxic alkaloids and avoid inadvertent poisoning [15] [16] [17] . Such obstacles encourage a good understanding of the relationships between structure and cytotoxic activity of aconitine and related compounds before they can be considered for modification and development as chemotherapeutic agents.
Our previous study demonstrated the effects of various naturally occurring and semi-synthetic C 19 -and C 20 -diterpenoid alkaloids on the growth of the A172 human malignant glioma cell line [18] . Antitumor properties and radiation-sensitizing effects of various types of novel derivatives prepared from C 19 -and C 20 -diterpenoid alkaloids were also investigated [19] . Two novel hetisine-type C 20 -diterpenoid derivatives showed significant suppressive effects against the Raji non-Hodgkin's lymphoma cell line [20] . In addition, the effects of various semi-synthetic novel hetisine-type C 20 -diterpenoid alkaloids on the growth of the A549 human lung cancer cell line were examined and subsequent structure-activity relationships for the antiproliferative effects against A549 cells were considered [21] . Since 2012, several diterpenoid alkaloid components and their derivatives exhibited antiproliferative activity against human tumor cell lines, including A549 (lung carcinoma), DU145 (prostate carcinoma), MDA-MB-231 (estrogen and progesterone receptor-negative & HER2-negative triple-negative breast cancer), MCF-7 (estrogen receptor-positive, HER2-negative breast cancer), KB (identical to cervical carcinoma HeLa derived AV-3 cell line), and multidrug-resistant (MDR) subline KB-VIN [P-glycoprotein (P-gp) overexpressing vincristine-resistant KB subline]. Among such alkaloids, C 19 -diterpenoid (e.g., lipojesaconitine, delpheline, and delcosine derivative) and C 20 -diterpenoid (e.g., kobusine and pseudokobusine derivatives) alkaloids have shown significant antiproliferative activity, as well as provided promising new leads for further development as antitumor agents.
Antiproliferative Activity of C 19 -Diterpenoid Alkaloid Derivatives
Aconitine-Type C 19 -Diterpenoid Alkaloids
The tested aconitine-type C 19 -diterpenoid alkaloids included 21 natural alkaloids, aconitine (1), deoxyaconitine (2), jesaconitine (3), deoxyjesaconitine (4), aljesaconitine A (5), secojesaconitine (6), mesaconitine (8) , hypaconitine (9), hokbusine A (10), 14-anisoyllasianine (12) , N-deethylaljesaconitine A (13), aconine (14) , lipomesaconitine (15) , lipoaconitine (16) , lipojesaconitine (17) , neolinine (18) , neoline (19), 14-benzoylneoline (20) , isotalatizidine (21) , karacoline (22) , and 3-hydroxykaracoline (23) , isolated from the rhizoma of Aconitum japonicum THUNB. subsp. subcuneatum (NAKAI) KADOTA [22] [23] [24] [25] [26] [27] [28] (Figure 2 ). Two synthetic aconitine-type C 19 -diterpenoid alkaloids, 3,15-diacetyljesaconitine (7) [26] and 3-acetylmesaconitine (11) [29] prepared from secojesaconitine (6) and mesaconitine (8) , respectively (Figure 2), were also tested.
8~10, 12~14, 18~23) and synthetic analogs (7 and 11), were inactive (IC50 > 20 or 40 μM) [27, 28, 30] (Table 1) . Three natural diterpenoid alkaloids (15~17) exhibited cytotoxic activity against five human tumor cell lines (A549, MDA-MB-231, MCF-7, KB, and MDR KB subline KB-VIN) ( Table 1) . Lipojesaconitine (17) showed significant cytotoxicity against four tested cell lines with IC50 values of 6.0 to 7.3 μM, but weak cytotoxicity against KB-VIN (IC50 = 18.6 μM) [28] . Lipomesaconitine (15) showed moderate cytotoxicity against the KB cell line (IC 50 = 9.9 μM), but weak cytotoxicity against the other four human tumor cell lines (IC50 =17.2 ~ 21.5 μM) [27] . Lipoaconitine (16) was weakly cytotoxic (IC50 = 13.7 ~ 20.3 μM) against all five human tumor cell lines [28] . Based on the results, the fatty acid ester at C-8 and the anisoyl group at C-14 found in 17 may be important to the cytotoxic activity of aconitine-type C19-diterpenoid alkaloids. Eighteen of the 23 tested aconitine-type C 19 -diterpenoid alkaloids, both natural alkaloids (1~6, 8~10, 12~14, 18~23) and synthetic analogs (7 and 11), were inactive (IC 50 > 20 or 40 µM) [27, 28, 30] (Table 1) . Three natural diterpenoid alkaloids (15~17) exhibited cytotoxic activity against five human tumor cell lines (A549, MDA-MB-231, MCF-7, KB, and MDR KB subline KB-VIN) ( Table 1) . Lipojesaconitine (17) showed significant cytotoxicity against four tested cell lines with IC 50 values of 6.0 to 7.3 µM, but weak cytotoxicity against KB-VIN (IC 50 = 18.6 µM) [28] . Lipomesaconitine (15) showed moderate cytotoxicity against the KB cell line (IC 50 = 9.9 µM), but weak cytotoxicity against the other four human tumor cell lines (IC 50 =17.2~21.5 µM) [27] . Lipoaconitine (16) was weakly cytotoxic (IC 50 = 13.72 0.3 µM) against all five human tumor cell lines [28] . Based on the results, the fatty acid ester at C-8 and the anisoyl group at C-14 found in 17 may be important to the cytotoxic activity of aconitine-type C 19 -diterpenoid alkaloids. 
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4.8 ± 0.6 5.9 ± 1.9 8.4 ± 0.8 10.2 ± 0.9 5.8 ± 0.2 2405.4 ± 44.8 1 Values are means ± standard deviation; 2 Paclitaxel (PXL; nM) was used as an experimental control.
Lycoctonine-Type (7,8-diol) C 19 -Diterpenoid Alkaloids
The tested lycoctonine-type (7,8-diol) C 19 -diterpenoid alkaloid group included 12 natural alkaloids, namely nevadensine (24) , N-deethylnevadensine (25) , and virescenine (27) , purified from rhizoma of Aconitum japonicum subsp. subcuneatum [27] , and 18-methoxygadesine (26) , delphinifoline (28) , delcosine (34), 14-acetyldelcosine (34-43), and 14-acetylbrowniine (35) , purified from root of Aconitum yesoense var. macroyesoense (NAKAI) TAMURA [31] [32] [33] [34] , and andersonidine (30) , pacifiline (31), pacifinine (32) , and pacifidine (33), purified from seeds of Delphinium elatum cv. Pacific Giant [35] (Figure 3 ). The remaining tested C 19 -diterpenoid alkaloids from this subtype were synthetic alkaloids, N-deethyldelsoline (29) [18] , 1-acetyldelcosine (34-1) [36] , 1,14-diacetyldelcosine (34-2) [37] , 1-(4-trifluoromethylbenzoyl)delcosine [30] , delsoline (34) (35) (36) (37) (38) (39) (40) (41) (42) [37], 1,14-di-(4-nitrobenzoyl)-delcosine (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) [30], 14-acetyl-1-(4-nitrobenzoyl)delcosine (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) [30] , and 1-acyl or 1,14-diacyldelcosine derivatives (34-3~34-23, 34-25~34-41, 34-44, and 34-47) [38] , prepared from delcosine (34) or delsoline (34) (35) (36) (37) (38) (39) (40) (41) (42) (Figure 3 ). These 42 C 19 -diterpenoid alkaloids were evaluated for antiproliferative activity against four to five human tumor cell lines (A549, DU145, MDA-MB-231, MCF-7, KB, and KB-VIN) [30, 38] (Table 2 ). Several tested lycoctonine-type (7,8- 
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1-(3,4,5-trimethoxybenzoyl)delcosine H 34-44 14-benzyldelcosine H CH2C6H5 Among the derivatives esterified at both C-1 and -14, alkaloids 34-19 and 34-20 exhibited significant potency against all five tested cell lines (average IC 50 4.9 and 5.0 µM, respectively). Alkaloid 34-9 (average IC 50 11.9 µM) showed significant antiproliferative activity against MDA-MB-231 and KB cells (IC 50 (34-4, 34-7, 34-9, 34-11, 34-14, 34-22, 34-23, 34-26, 34-28 and 34-36) . Thus, a C-1 acyloxy group and C-14 hydroxy group are crucial for enhanced antiproliferative activity of 1-derivatives. Regarding alkaloids 34-18 (pentafluorobenzoate at C-1, hydroxy at C-14), 34-19 (pentafluorobenzoate at C-1 and C-14), and 34-20 (pentafluorobenzoate at C-1, acetate at C-14), all three alkaloids were essentially equipotent against three of the five tumor cell lines, while 34-18 was somewhat less potent than the diacylated alkaloids against MCF-7 and KB-VIN cells.
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Striking observations from the data in Table 2 were the consistent identities of the most potent alkaloids. Alkaloids 34-8, 34-10, 34-19, and 34-20 Interestingly, the active alkaloids were generally effective against P-gp overexpressing MDR subline KB-VIN, while alkaloids such as vincristine and paclitaxel are ineffective due to excretion from the MDR cells by P-gp. These results suggest that these diterpenoids are not substrates for P-gp.
Lycoctonine-Type (7,8-methylenedioxy) C 19 -Diterpenoid Alkaloids
The tested lycoctonine-type (7,8- 
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Lycoctonine-Type (7,8-methylenedioxy) C19-Diterpenoid Alkaloids
methylenedioxy) C19-diterpenoid alkaloids included 19 natural alkaloids, delcorine (36), delpheline (37), pacinine (38), yunnadelphinine (39), melpheline (40), bonvalotidine C (41), N-deethyl-N-formylpaciline (42), N-deethyl-N-formylpacinine (43), isodelpheline (44), pacidine (45), eladine (46), N-formyl-4,19-secopacinine (47), N-formyl-4,19-secoyunnadelphinine (48), iminoisodelpheline (49), iminodelpheline (50), laxicyminine (51), N-deethyl-19-oxoisodelpheline (52), N-deethyl-19-oxodelpheline (53)
, and 19-oxoisodelpheline (54), purified from seeds of Delphinium elatum cv. Pacific Giant [35, [39] [40] [41] [42] (Figure 4 ). The remaining 22 tested C19-diterpenoids were synthetic derivatives (37-1~37-22) [43] prepared from 37 ( Figure 4) .
All tested lycoctonine-type (7,8-methylenedioxy) C19-diterpenoid alkaloids were evaluated for antiproliferative activity against human tumor cell lines [30, [40] [41] [42] [43] (Table 3 ). The lycoctonine-type (7,8-methylenedioxy) C19-diterpenoid alkaloids, both the natural alkaloids (36~54) and synthetic analogs that did not contain a C-6 ester group (37-20 and 37-22), were inactive (IC50 > 20 or 40 μM). Among the C-6 esterified alkaloids, 37-1, 37-17, and 37-18 exhibited the highest average potency toward four tested cell lines (A549, DU145, KB and KB-VIN; average IC50 9.83, 9.57, and 9.41 μM, respectively). Alkaloids 37-3, 37-5~37-7, 37-9, 37-10, 37-12, 37-13, 37-16, and 37-19 showed moderate potency against all tested cell lines (average IC50 13.9−20.8 μM). However, alkaloid 37-13 showed significantly increased cytotoxic activity (IC50 10.2 μM) against A549 cells compared with 37-1, 37-17, and 37-18, but was generally less potent against DU145 and KB cells. While alkaloids 37-12, 37-13, 37-16, and 37-19 displayed good antiproliferative activity (IC50 6.8, 9.1, 6.5, and 4.7 μM, respectively) against KB-VIN cells, they were much less potent against A549, DU145, and KB cells. Alkaloids 37-4 and 37-21 were inactive against all tested cancer cell lines, while 37-2, 37-8, 37-11, and 37-14 exhibited only weak potency toward all cell lines (average IC50 23.0−29.2 μM).
The most noticeable observations from the data in Table 3 were the degree and relative ratio of KB/KB-VIN potency. Among the four cancer cell lines tested, the highest potency was found against the KB-VIN cell line by alkaloids 37-17~37-19 (IC50 4.22, 4.40, and 4.71 μM, respectively), followed by alkaloids 37-16, 37-12, 37-1, 37-13, and 37-9 (IC50 6.50, 6.80, 8.27, 9.10, and 11.9 μM, respectively). Generally, all active alkaloids showed the highest potency against the KB-VIN cell line compared with the other three tested cancer cell lines. Moreover, alkaloids 37-12, 37-16, 37-13, and 37-19 showed over two-fold selectivity between the two cell lines (ratio of IC50 KB/IC50 KB-VIN: 2.15, 2.28, 2.31, and All tested lycoctonine-type (7,8-methylenedioxy) C 19 -diterpenoid alkaloids were evaluated for antiproliferative activity against human tumor cell lines [30, [40] [41] [42] [43] (Table 3 ). The lycoctonine-type (7,8-methylenedioxy) C 19 -diterpenoid alkaloids, both the natural alkaloids (36~54) and synthetic analogs that did not contain a C-6 ester group (37-20 and 37-22), were inactive (IC 50 > 20 or 40 µM). Among the C-6 esterified alkaloids, 37-1, 37-17, and 37-18 exhibited the highest average potency toward four tested cell lines (A549, DU145, KB and KB-VIN; average IC 50 9.83, 9.57, and 9.41 µM, respectively). Alkaloids 37-3, 37-5~37-7, 37-9, 37-10, 37-12, 37-13, 37-16, and 37-19 showed moderate potency against all tested cell lines (average IC 50 13.9−20.8 µM). However, alkaloid 37-13 showed significantly increased cytotoxic activity (IC 50 10.2 µM) against A549 cells compared with 37-1, 37-17, and 37-18, but was generally less potent against DU145 and KB cells. While alkaloids 37-12, 37-13, 37-16, and 37-19 displayed good antiproliferative activity (IC 50 6.8, 9.1, 6.5, and 4.7 µM, respectively) against KB-VIN cells, they were much less potent against A549, DU145, and KB cells. Alkaloids 37-4 and 37-21 were inactive against all tested cancer cell lines, while 37-2, 37-8, 37-11, and 37-14 exhibited only weak potency toward all cell lines (average IC 50 23.0−29.2 µM).
The most noticeable observations from the data in Table 3 were the degree and relative ratio of KB/KB-VIN potency. Among the four cancer cell lines tested, the highest potency was found against the KB-VIN cell line by alkaloids 37-17~37-19 (IC 50 4.22, 4.40, and 4.71 µM, respectively), followed by alkaloids 37-16, 37-12, 37-1, 37-13, and 37-9 (IC 50 6.50, 6.80, 8.27, 9.10, and 11.9 µM, respectively). Generally, all active alkaloids showed the highest potency against the KB-VIN cell line compared with the other three tested cancer cell lines. Moreover, alkaloids 37-12, 37-16, 37-13, and 37-19 showed over two-fold selectivity between the two cell lines (ratio of IC 50 KB/IC 50 KB-VIN: 2.15, 2.28, 2.31, and 2.57, respectively). Alkaloids 37-2, 37-5, and 37-17 displayed weak selectivity between the KB and KB-VIN cell lines (ratio of IC 50 KB/IC 50 KB-VIN: 1.55, 1.36, and 1.62, respectively). Finally, alkaloids 37-1, 37-3, 37-6~37-9, 37-11, 37-14, 37-15, and 37-18 displayed similar potency against the KB and KB-VIN cell lines (ratio of IC 50 KB/IC 50 KB-VIN: 1.07, 1.17, 1.06, 1.21, 1.04, 1.25, 1.07, 1.07, 1.17, and 1.23, respectively).
The identity of the substituent on the C-6 acyl group affected the cytotoxic potency. For instance, the alkaloids with the highest potency against the KB-VIN cell line contained chloro (37-1), fluoro (37- 12, 37-18, and 37-19) , trifluoromethyl (37-9, 37-13, and 37-18), ethoxy (37-16), or benzyloxy substituents on the acyl group. Against the KB-VIN cell line, alkaloids 37-18 and 37-19 with both fluoro and trifluoromethyl/methyl groups were more potent than 37-9 with only a single trifluoromethyl group and even more potent than 37-2 with a single fluoro group. Similarly, alkaloid 37-13 showed increased cytotoxic activity against most cell lines compared with the related fluorinated alkaloids 37-14 and 37-15. Moreover, alkaloids with nitro, methoxy, phenyl, trifluoromethoxy, trifluoromethythio, and methyl carboxylate groups on a C-6 benzoate ester were generally less potent. 
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Values are means ± standard deviation; 2 Paclitaxel (PXL; nM) was used as an experimental control.
Antiproliferative Activity of C 20 -Diterpenoid Alkaloid Derivatives
Actaline and Napelline-Type C 20 -Diterpenoid Alkaloids
One natural actaline-type C 20 -diterpenoid alkaloid [44] , aconicarchamine A (55), isolated from rhizoma of Aconitum japonicum subsp. subcuneatum [30] , ( Figure 5 ) and seven natural napelline-type C 20 -diterpenoid alkaloids, lucidusculine (57), flavadine (58), 12-acetyllucidusculine (59), 1-acetyl-luciculine (60), dehydrolucidusculine (61), dehydroluciculine (62), and 12-acetyldehydroluciduscu-line (63), purified from roots of Aconitum yesoense var. macroyesoense [31] [32] [33] , ( Figure 5 ) were tested. Seven synthetic napelline-type C 20 -diterpenoid alkaloid derivatives (56-1~56-7) [18, 32, 45] were prepared from luciculine (56) ( Figure 5) and tested also. All tested actaline-and napelline-type C 20 -diterpenoid alkaloids were evaluated for antiproliferative activity against four to five human tumor cell lines [28, 30] (Table 4) . Tested actaline-and napelline-type C 20 -diterpenoid alkaloids, both the natural alkaloids (55 and 57~63) and synthetic analogs (56-1~56-4, 56-6, and 56-7), were inactive (IC 50 > 20 or 40 µM). Among the synthetic alkaloids, alkaloid 56-5 exhibited only weak potency toward the tested cell lines (A549, DU145, KB and KB-VIN; average IC 50 27.8 µM). Because the related alkaloids 57, 60, 56-2~56-4, 56-6, and 56-7 were inactive against all tested cancer cell lines, a C-1 hydroxy group, C-12 acyloxy group, and C-15 acetoxy group found in 56-5 could be needed for antiproliferative activity of luciculine derivatives. 
37-13
showed increased cytotoxic activity against most cell lines compared with the related fluorinated alkaloids 37-14 and 37-15. Moreover, alkaloids with nitro, methoxy, phenyl, trifluoromethoxy, trifluoromethythio, and methyl carboxylate groups on a C-6 benzoate ester were generally less potent.
Antiproliferative Activity of C20-Diterpenoid Alkaloid Derivatives
Actaline and Napelline-Type C20-Diterpenoid Alkaloids
One natural actaline-type C20-diterpenoid alkaloid [44] , aconicarchamine A (55), isolated from rhizoma of Aconitum japonicum subsp. subcuneatum [30] , ( Figure 5 ) and seven natural napelline-type C20-diterpenoid alkaloids, lucidusculine (57), flavadine (58), 12-acetyllucidusculine (59), 1-acetylluciculine (60), dehydrolucidusculine (61), dehydroluciculine (62), and 12-acetyldehydrolucidusculine (63), purified from roots of Aconitum yesoense var. macroyesoense [31] [32] [33] , ( Figure 5 ) were tested. Seven synthetic napelline-type C20-diterpenoid alkaloid derivatives (56-1~56-7) [18, 32, 45] were Table 4 . Cytotoxic activity data for actaline and napelline-type C20-diterpenoid alkaloids 55~63 and synthetic analogs 56-1~56-7 of luciculine. 
23.3 ± 6.1 28.1 ± 11.1 --31.8 ± 10.5 27.8 ± 1.9 56-6 >20 >20 -->20 >20 56-7 >20 >20 -->20 >20 
Hetisine-Type (Analogs of Kobusine) C 20 -Diterpenoid Alkaloids
Tested hetisine-type (analogs of kobusine) C 20 -diterpenoid alkaloids included four natural alkaloids, ryosenamine (64), 9-hydroxynominine (65), and torokonine (66), isolated from rhizoma of Aconitum japonicum subsp. subcuneatum [27, 28] (Figure 6 ) and kobusine (67), purified from roots of Aconitum yesoense var. macroyesoense [31] (Figure 6 ). Nineteen synthetic derivatives (67-1~67-19) [18, 21, 30, 46, 47] (Figure 6 ) prepared from 67 were tested also.
All tested hetisine-type (kobusine analogs) C 20 -diterpenoid alkaloids were evaluated for antiproliferative activity against four human tumor cell lines [27, 28, 30] (Table 5) . Fifteen of the 23 alkaloids, both natural (64~67) and synthetic (67-1~67-4, 67-6, 67-9, 67-11, 67-12, 67-15~67-17), Among the analogs of 68, four C-11 mono-substituted alkaloids (68-15, 68-20, 68-24, and 68-32) and two C-11,15 di-esterified alkaloids (68-5 and 68-19) exhibited average IC 50 values of less than 10 µM. Certain C-11 (68-7, 68-10, and 68-22), C-6,11 (68-4 and 68-12) and C-6,15 (68-13) esterified alkaloids were generally less potent, while all C-6 (68-3, 68-6, 68-14, and 68-23) and C-15 (68-1, 68-11,  68-16, 68-25, 68-28, and 68-30 ) mono-substituted alkaloids, as well as the tri-substituted analog (68-18), were inactive. Thus, all more active (IC 50 < 10 µM) C 20 -diterpenoid alkaloids in this classification had an ester or ether group on the C-11 hydroxy and were 11-monoester/11,15-diester analogs of 68 (OH at C-6).
The data in Table 6 led to noticeable observations about the degree and comparative ratio of KB/KB-VIN potency. Six alkaloids (68-5, 68-15, 68-19, 68-20, 68-24 , and 68-32) were quite potent (IC 50 < 10 µM) against KB-VIN. Indeed, alkaloid 68-32 exhibited a low IC 50 value of 5.2 µM. The ratios of KB to KB-VIN (IC 50 KB/IC 50 KB-VIN) were greater than 0.70 for all active alkaloids, with many alkaloids displaying comparable potency against the two cell lines, in contrast with paclitaxel (ratio of 0.0067).
Alkaloids 68-12, 68-13, and 68-20 showed over 1.3-fold selectivity with their greatest cytotoxic activity against KB-VIN (IC 50 KB/IC 50 KB-VIN: 1.34, 1.48, and 1.44, respectively).
In mechanism of action studies on selected diterpenoid alkaloids, the hetisine-type C 20 -diterpenoid alkaloid derivatives 68-7 and 68-22 showed important suppressive effects against Raji cells. Further study indicated that 68-22 inhibited extracellular signal-regulated kinase phosphorylation but induced enhanced phosphoinositide 3 kinase phosphorylation, leading to accumulation of Raji cells in the G1 or sub G1 phase [20] . More investigation is certainly warranted.
Discussion
We have synthesized acylated derivatives of various C 19 -and C 20 -diterpenoid alkaloids. Totally, 199 natural alkaloids and their derivatives were evaluated against four to five human tumor cell lines. Among all alkaloids, 128 alkaloids were non-toxic (IC 50 > 20 or 40 µM) and 51 alkaloids showed moderate antiproliferative effects (average IC 50 = 10-40 µM). General summaries are described briefly below, and the most active compounds are shown in Figure 8 . fluorinated benzoyl esters. In addition, among 19 tested delpheline derivatives, four compounds (37-12, 37-16, 37-13, and 37-19) showed over two-fold selectivity between the MDR and parental cell lines (ratio of IC50 KB/IC50 KB-VIN: 2. 15, 2.28, 2.31, and 2.57, respectively) .
None of the 15 tested actaline-and napelline-type C20-diterpenoid alkaloids showed significant antiproliferative potency. Only 12-benzoyllucidsuculine (56-5) with C-1 hydroxy, C-12 acyloxy, and C-15 acetoxy groups showed even weak potency.
Among C20-diterpenoid alkaloids, the most active alkaloids were hetisine-type C20-diterpenoid alkaloids with two different substitution patterns, C-11,15 (kobusine) and C-6,11,15 (pseudokobusine). Hetisine-type C20-diterpenoid alkaloids 67-5, 67-7, 67-10, 67-18, 67-19, 68-5, 68-15, 68-19, 68-20, 68-25, and 68-32, which are acylated or tritylated at the C-11 hydroxyl, exhibited the greatest potency over all tested cell lines, including MDR KB-VIN. All five most active kobusine derivatives (67-5, 67-7, 67-10, 67-18, and 67-19 ) are acylated at both C-11 and C-15. All tested derivatives with a hydroxy group at either C-11 or C-15 were inactive or much less active. All six most active pseudokobusine derivatives (68-5, 68-15, 68-19, 68-20, 68-25, and 68-32 ) contain a free hydroxy group at C-6. The substituent at C-11 is either a benzoyl/cinnamoyl ester (68-5, 68-15, 68-19, 68-20, and 68-25) or a  trityl ether (68-32) . Finally, the moiety at C-15 is a hydroxy group (68-15, 68-20, 68-25, and 68-32) or benzoyl ester (68-5, 68-19) .
Furthermore, previously our study, Antitumor properties and radiation-sensitizing effects of various types of novel derivatives prepared from C19-and C20-diterpenoid alkaloids were also investigated [19] . Two novel hetisine-type C20-diterpenoid derivatives (68-7 and 68-20) showed significant suppressive effects against the Raji non-Hodgkin's lymphoma cell line [20] . Among the aconitine-type C 19 -diterpenoid alkaloids, the fatty acid ester at C-8 and the anisoyl group at C-14 found in 17 may be important to the cytotoxic activity. Compounds without the fatty acid ester at C-8 were inactive, and compounds with an unsubstituted benzoyl group at C-14 were less potent.
Among the C 19 -diterpenoid alkaloids, the most active alkaloids were lycoctonine-type C 19 -diterpenoid alkaloids with two different substitution patterns, C-1 (delcosine derivatives) and C-6 (delpheline derivatives). Delcosine derivatives 34-6, 34-8, 34-10, and 34-18, which are acylated at the C-1 hydroxy, as well as delpheline derivatives 37-1, 37-17, and 37-18, which are acylated at the C-6 hydroxy, exhibited the greatest potency over all tested cell lines, including MDR KB-VIN.
Among the lycoctonine-type (7,8-diol) C 19 -diterpenoid alkaloids, a C-1 acyloxy group and C-14 hydroxy group were important for improved antiproliferative activity. The C-1,14 diacylated delcosine derivatives were generally less potent than corresponding C-1 monoacylated delcosine derivatives. The 1-monoacylated alkaloids with the highest potency (IC 50 4−6 µM) against five tested cell lines contained 3-nitro-4-chloro-(34-8) and pentafluoro-(34-18) as well as 4-dichloromethyl-(34-10) benzoyl esters. Two or one pentafluorinated benzoyl esters were also found in the two most consistently potent alkaloids (34- 19 and 34-20) among the 1,14-diacyl and 1-acyl-14-acetyl derivatives.
Among the lycoctonine-type (7,8-methylenedioxy) C 19 -diterpenoid alkaloids, none of the tested compound reached the potency levels of the most active 7,8-diol compounds. However, three 6-acylated delpheline derivatives 37-17~37-19 did show significant potency against the KB-VIN cell line (IC 50 4.22, 4.40, and 4.71 µM, respectively). Interestingly, the two latter compounds contained fluorinated benzoyl esters. In addition, among 19 tested delpheline derivatives, four compounds (37-12, 37-16, 37-13, and 37-19) showed over two-fold selectivity between the MDR and parental cell lines (ratio of IC 50 KB/IC 50 KB-VIN: 2.15, 2.28, 2.31, and 2.57, respectively).
None of the 15 tested actaline-and napelline-type C 20 -diterpenoid alkaloids showed significant antiproliferative potency. Only 12-benzoyllucidsuculine (56-5) with C-1 hydroxy, C-12 acyloxy, and C-15 acetoxy groups showed even weak potency.
Among C 20 -diterpenoid alkaloids, the most active alkaloids were hetisine-type C 20 -diterpenoid alkaloids with two different substitution patterns, C-11,15 (kobusine) and C-6,11,15 (pseudo-kobusine). Hetisine-type C 20 -diterpenoid alkaloids 67-5, 67-7, 67-10, 67-18, 67-19, 68-5, 68-15, 68-19, 68-20, 68-25, and 68-32, which are acylated or tritylated at the C-11 hydroxyl, exhibited the greatest potency over all tested cell lines, including MDR KB-VIN. All five most active kobusine derivatives (67-5, 67-7, 67-10, 67-18, and 67-19) are acylated at both C-11 and C-15. All tested derivatives with a hydroxy group at either C-11 or C-15 were inactive or much less active. All six most active pseudo-kobusine derivatives (68-5, 68-15, 68-19, 68-20, 68-25, and 68-32) contain a free hydroxy group at C-6. The substituent at C-11 is either a benzoyl/cinnamoyl ester (68-5, 68-15, 68-19, 68-20, and 68-25) or a trityl ether (68-32). Finally, the moiety at C-15 is a hydroxy group (68-15, 68-20, 68-25, and 68-32) or benzoyl ester (68-5, 68-19).
Furthermore, previously our study, Antitumor properties and radiation-sensitizing effects of various types of novel derivatives prepared from C 19 -and C 20 -diterpenoid alkaloids were also investigated [19] . Two novel hetisine-type C 20 -diterpenoid derivatives (68-7 and 68-20) showed significant suppressive effects against the Raji non-Hodgkin's lymphoma cell line [20] .
Conclusions
We have synthesized acylated derivatives of various C 19 -and C 20 -diterpenoid alkaloids. All alkaloids and their derivatives were screened against four to five human tumor cell lines. Alkaloids  37-2, 37-9, 37-17, 37-18, 56-5, 67-7, 67-14, 67-19, 68-4, 68-12, 68-20, 68-22, 68-24 , and 68-32 showed comparable potency against KB and KB-VIN cancer cell lines, and some alkaloids showed tumorselective activity. Alkaloids 37-12, 37-13, 37-16, and 37-19 exhibited greater inhibitory activity against drug-resistant KB-VIN cells (2.15~2.57-fold) than the parental KB cells. These results demonstrate that modified lycoctonine-type C 19 -diterpenoid alkaloids and hetisine-type C 20 -diterpenoid alkaloids are not substrates of P-gp and could be effective against P-gp overexpressing MDR tumors. These promising new lead alkaloids merit continued studies to evaluate their potential as antitumor agents, particularly with enhanced resistant tumor selectivity. In addition, our results from modification-based antitumor activity studies can be used for further development of anticancer drugs overcoming an MDR phenotype.
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